Ocorrência de Babesia sp, Ehrlichia canis e Hepatozoon canis em cães domiciliados, em dois municípios do estado do Espírito Santo - Brasil / Occurrence of Babesia sp, Ehrlichia canis and Hepatozoon canis in domiciled dogs in two municipalities of the state of Espírito Santo - Brazil / Ocurrencia de Babesia sp, Ehrlichia canis y Hepatozoon canis em perros domiciliados em dos municipios del estado de Espírito Santo - Brasil

As doenças transmitidas por carrapatos são afecções de grande importância na clínica médica de pequenos animais, devido à alta casuística e ampla distribuição vetorial no território brasileiro. Os principais agentes responsáveis pelas infecções em cães são Babesia sp., Ehrlichia canis e Hepatozoon canis. Os animais infectados são assintomáticos ou apresentam sinais clínicos inespecíficos, sendo necessário a utilização de testes diagnósticos para definição do agente etiológico, e diagnóstico seguro. O objetivo do presente estudo foi determinar a ocorrência desses micro-organismos em cães naturalmente infectados, domiciliados nos municípios de Vila Velha e Anchieta, Espírito Santo, utilizando diferentes testes de detecção: Reação em cadeia polimerase (PCR), sorologia para detecção de anticorpos anti Ehrlichia canis e pesquisa de hematozoários em esfregaço sanguíneo. Foram analisadas 65 amostras de sangue obtidas por venopunção de veia cefálica de cães. No teste de PCR, 4,62% dos animais foram positivos para Babesia vogeli e 1,54% para Ehrlichia canis sendo os resultados para Hepatozoon canis negativos. No teste sorológico para E. canis 90,77% dos animais foram positivos para a presença de anticorpos, e na pesquisa em lâminas de esfregaço sanguíneo 3,02% apresentavam outros hemoparasitas. Os resultados indicam a dispersão desses hemoparasitas na população canina da região de estudo, entretanto com baixa ocorrência. O teste de PCR demonstrou-se como o mais sensível no qual Babesia vogeli foi o agente mais observado.(AU)

Tick-borne diseases are diseases of great importance in the medical practice of small animals, due to the high casuistry and wide vectorial distribution in the Brazilian territory. The main agents responsible for infections in dogs are Babesia sp., Ehrlichia canis and Hepatozoon canis. Infected animals are asymptomatic or present nonspecific clinical signs, requiring the use of diagnostic tests to define the etiologic agent, and safe diagnosis. The objective of the present study was to determine the occurrence of these microorganisms in naturally infected dogs domiciled in the municipalities of Vila Velha and Anchieta, Espírito Santo, using different detection tests: polymerase chain reaction (PCR), serology to detect antibodies against Ehrlichia canis and research of hematozoa in blood smears. Sixty-five blood samples obtained by venipuncture of the cephalic vein of dogs were analyzed. In the PCR test, 4.62% of the animals were positive for Babesia vogeli and 1.54% for Ehrlichia canis, and the results for Hepatozoon canis were negative. In the serological test for E. canis, 90.77% of the animals were positive for the presence of antibodies, and in the research in blood smear slides, 3.02% presented other hemoparasites. The results indicate the dispersion of these hemoparasites in the canine population of the study region, however with low occurrence. The PCR test proved to be the most sensitive, in which Babesia vogeli was the most observed agent.(AU)

Las enfermedades transmitidas por garrapatas son enfermedades de gran importancia en la práctica médica de los pequeños animales, debido a la alta casuística y amplia distribución vectorial en el territorio brasileño. Los principales agentes responsables de las infecciones en los perros son Babesia sp., Ehrlichia canis y Hepatozoon canis. Los animales infectados son asintomáticos o presentan signos clínicos inespecíficos, siendo necesario el uso de pruebas diagnósticas para la definición del agente etiológico, y el diagnóstico seguro. El objetivo del presente estudio fue determinar la ocurrencia de estos microorganismos en perros infectados naturalmente, domiciliados en los municipios de Vila Velha y Anchieta, Espírito Santo, utilizando diferentes pruebas de detección: reacción en cadena de la polimerasa (PCR), serología para detectar anticuerpos anti Ehrlichia canis e investigación de hematozoos en frotis de sangre. Se analizaron sesenta y cinco muestras de sangre obtenidas por venopunción de la vena cefálica de los perros. En la prueba PCR, el 4,62% de los animales fueron positivos para Babesia vogeli y el 1,54% para Ehrlichia canis, y los resultados para Hepatozoon canis fueron negativos. En la prueba serológica para E. canis, el 90,77% de los animales fueron positivos a la presencia de anticuerpos, y en la investigación en láminas de frotis de sangre el 3,02% presentaron otros hemoparásitos. Los resultados indican la dispersión de estos hemoparásitos en la población canina de la región de estudio, aunque con una baja presencia. La prueba PCR resultó ser la más sensible, en la que Babesia vogeli fue el agente más observado.(AU)

Evaluation of Abbott Architect, Siemens Immulite, bioMerieux Vidas, and Euroimmune assays for determination of Epstein-Barr virus serological diagnosis.

Serological tests detecting antibodies for Epstein-Barr virus (EBV) antigens are frequently used to define infection status. Several new automated assays are available for this purpose. We compared the performance of Architect, Immulite, Vidas, and Euroimmune immunofluorescence assays (IFA)/enzyme-linked immunosorbent assays (ELISA) for the detection of EBV viral capsid antigen (VCA) immunoglobulin M (IgM), VCA IgG, Epstein-Barr nuclear antigen (EBNA)-1 IgG. The routine diagnosis of EBV in our laboratory is done by anti-EBV VCA IgM IFT, anti-EBV VCA IgG IFT, and anti-EBNA-1 IgG ELISA (Euroimmune) Kits. Samples were tested with EBV Kits of Architect, Immulite, and Vidas for anti-VCA IgM, anti-VCA IgG, and anti-EBNA-1 IgG. The agreement between assays was calculated for each marker individually and for the determination of the EBV infection profile, based on the combination of three markers. BIOCHIP Sequence EBV (Avidity test) and/or EUROLINE EBV Profile 2 (IgG/IgM) were used as confirmatory assays to resolve discrepancies. The best concordance for VCA IgM detection was between Immulite and Vidas; for VCA IgG and EBNA-1 IgG were between Architect and Vidas. The sensitivities and specificities for VCA IgM were 97% and 88% for IFA, 100% and 94% for Architect, 100% and 99% for Vidas, and 100% and 100% for Immulite, respectively. The most problematic marker was EBNA-1 IgG with a 68.1% specificity by Immulite. Vidas panel had a perfect performance (100%) for determining all EBV profiles. Overall, evaluated assays had comparable performance. There were more discordant VCA IgG and EBNA-1 IgG results than VCA IgM results. The agreement between Architect and Vidas was better than other assays.

Evaluation of 2 Commercially Systems for Detection of Serum Squamous Cell Carcinoma Antigen in Pan Squamous Cell Carcinoma.

BACKGROUND: This study compared the analytical performance of the Elecsys 602 (Roche Diagnostics) system with the I2000 (Abbott laboratories) system for the quantitative measurement of squamous cell carcinoma antigen (SCCA) to assess its role as an indicator in pan squamous cell carcinoma. METHODS: 435 serum samples included pan squamous cell cancer group (n = 318) and healthy subjects (n = 52) and non-squamous cell group (n = 41) and benign diseases group (n = 24) were measured by 2 systems and compared. RESULTS: The within-run precision coefficient of variation (CV) for Abbott and Roche systems were 3.34-4.88% and 0.95 -1.96%, and the total precision CV were 2.89-9.48% and 3.97-5.38%, respectively. Good correlation was showed in Abbott and Roche systems (slopes = 0.749, r = 0.9658). Serum SCCA in the groups of nasopharyngeal carcinomas, lung squamous cell carcinoma, esophageal squamous cell carcinoma, bladder cancer and cervical squamous cell carcinoma under the curve area (AUC) was more than 0.5, while the AUC in the non- nasopharyngeal carcinomas head and neck squamous cell carcinoma was less than 0.5. The AUC of 2 systems was statistically different in lung squamous cell carcinoma and nasopharyngeal carcinomas (P < 0.05). The levels of SCCA of 2 systems were similarities in esophageal squamous cell carcinoma(stage IV vs. stage 0a-II)and bladder cancer(stage I vs. stage Oa)and cervical squamous cell carcinoma(stage IIB-III vs. stage I-IIA), which advanced stage had higher level of SCCA than early stage. But the SCCA levels of 2 systems were inconsistent in bladder cancer (stage II-IV vs. stage Oa in Abbott), head and neck squamous cell carcinoma (stage IV vs. stage Oa-I in the Roche) and lung squamous cell carcinoma (stage III vs. stage I-II in the Roche). (P < 0.05). CONCLUSIONS: 2 systems correlated well in SCCA detection of squamous cell carcinoma, but there were individual differences. Serum SCCA may also contribute to the diagnosis of bladder cancer.

Head-to-Head Comparison of Two SARS-CoV-2 Serology Assays.

BACKGROUND: While molecular techniques remain the gold standard for diagnosis of acute SARS-CoV-2 infection, serological tests have the unique potential to ascertain how much of the population has been exposed to the COVID-19 pathogen. There have been limited published studies to date documenting the performance of SARS-CoV-2 antibody assays. METHODS: We compared the DiaSorin Liaison SARS-CoV-2 S1/S2 IgG and Roche Diagnostics Elecsys Anti-SARS-CoV-2 assays using 228 samples spanning patients with positive PCR for SARS-CoV-2, patients with compatible symptoms but negative PCR, pre-COVID specimens, and potential cross-reactives. RESULTS: Both assays detected antibodies in 18/19 samples collected at least one week after a positive PCR result. Neither method consistently detected antibodies in specimens collected within one week of a positive PCR result (sensitivity < 50%), but antibodies were detected by only Roche in four samples in this time frame. Using 139 pre-COVID and 35 PCR-negative samples, the Roche and DiaSorin assays demonstrated specificities of 100.0% and 98.9%, respectively. Neither assay demonstrated cross-reactivity from other coronaviruses (229E, HKU1, NL63, OC43), respiratory pathogens (adenovirus, metapneumovirus, rhinovirus/enterovirus), or antibodies to other viruses (HIV, EBV, CMV, HBV, HCV, HAV). DISCUSSION: Overall, the qualitative interpretations afforded by the Roche and DiaSorin assays agreed for 97% of samples evaluated. Minor discrepancies in sensitivity and specificity were observed between methods, with the differences in specificity more clinically significant for our low-prevalence population. For the DiaSorin assay, all disagreements with the Roche assay occurred in samples with quantitative signals near the cut-off determining positivity.

Architect i2000 SR has improved turnaround time for infectious disease serology testing over Vitros ECiQ.

BACKGROUND: Vitros ECiQ and Architect i2000 SR are two automated instruments used to detect serology biomarkers of hepatitis A, B and C viruses, and HIV infections. We compared performance of the Architect to the Vitro EciQ after implementation at our institution. METHODS: A retrospective review was performed to compare patient samples tested on the Vitros ECiQ or Architect for hepatitis and HIV serological assays. The positivity rate, frequency of equivocal results, turnaround times (TAT), and hands-on time (HOT) were analyzed. RESULTS: There was no statistical difference in the positivity rate between the two instruments, with the exception of two assays. An increase in equivocal results was observed for the Architect (0.2% vs 0.5%). Notably, the TAT for the Architect i2000 was shorter for all except one assay (31.6 vs 33.7 hours) and demonstrated improved workflow. CONCLUSIONS: Overall, both instruments performed comparably. Architect had shorter TAT over Vitros.

Uso complementario de las pruebas moleculares y pruebas de detección de anticuerpos para el diagnóstico de COVID-19 / Complementary use of molecular tests and antibody screening tests for the diagnosis of COVID-19

ANTECEDENTES: El COVID-19 es una infección producida por una cepa de coronavirus denominada SARS-CoV-2. En la actualidad, esta infección es una pandemia que afecta a más de 209 países y territorios a nivel mundial. En el Perú, se han reportado hasta el 07 de abril de 2020, 2 954 casos y un total de 107 fallecidos. El diagnóstico rápido de la infección juega un papel importante en el manejo de la enfermedad y de los brotes, permitiendo implementar medidas de vigilancia, prevención y control. Una dificultad para el diagnóstico oportuno es la gran proporción de portadores asintomáticos del virus, quienes representan un contribuyente importante en la propagación de la enfermedad. El método estándar para el diagnóstico de COVID-19 es la prueba molecular basada en la reacción en cadena de la polimerasa con transcriptasa inversa (RT-PCR). Sin embargo, esta prueba presenta algunas limitaciones como el alto costo, la necesidad de procesamiento por personal especializado, en un laboratorio con medidas de bioseguridad, la posibilidad inicial de falsos negativos y la tendencia a negativizarse conforme transcurre la enfermedad. Asimismo, existen pruebas basadas en la detección de anticuerpos, principalmente inmunoglobulinas (Ig) M y G. Estas pruebas podrían usarse en la comunidad, no requieren personal altamente calificado ni condiciones estrictas de operación como en caso de las pruebas de RT-PCR. Sin embargo, pueden pasar algunos días desde el inicio de la infección hasta que se produzcan anticuerpos detectables. La utilización complementaria de ambas pruebas podría mejorar la identificación correcta de pacientes con COVID-19, incluyendo a los pacientes asintomáticos o con enfermedad leve, contribuyendo a disminuir su propagación. OBJETIVO: Describir la evidencia científica disponible sobre la utilidad del uso complementario de pruebas moleculares y de detección de anticuerpos para mejorar el diagnóstico de sospechosos de COVID-19. MÉTODO: Búsqueda sistemática de estudios en idioma español o inglés publicados entre el 01 de diciembre de 2019 y el 04 de abril de 2020 en Medline, Cochrane Central Register of Controlled Trials (CENTRAL), MedRxiv, Chinese Clinical Trial Registry (CCTR), y LILACS, complementada con una búsqueda de literatura gris en Google Scholar. RESULTADOS: Se incluyeron 06 estudios que respondieron a la pregunta PICO de interés Tres estudios evaluaron la variación de sensibilidad de diferentes pruebas para el diagnóstico de COVID-19 según los días transcurridos desde el inicio de síntomas. Estos estudios coinciden en observar mayor sensibilidad de las pruebas de RT-PCR durante los primeros siete días del inicio de síntomas (rango: 66,7% a 100%), en comparación con las pruebas de detección de anticuerpos totales (rango: 38,3% a 64,1%), IgG (rango: 19,1% a 53,8%) o IgM (rango: 23,0% a 33,3%). En el intervalo mayor de tiempo de medición de los estudios considerando el inicio de síntomas (más de 15 días), se observó una reversión de la tendencia, con una mayor sensibilidad de la prueba de anticuerpos totales (100% en dos estudios), IgM (rango: 52,2% a 96,7%) e IgG (rango: 79,8% a 93,3%), en comparación con las pruebas de RT-PCR (rango: 13% a 70,7%). Un estudio comparó la disminución de sensibilidad de la prueba de RT-PCR según el tipo de muestra, observando que en las muestras obtenidas de hisopado nasofaríngeo la disminución de sensibilidad fue más acentuada (desde 69,2% a los 7 días, hasta 13% a más de 15 días), en comparación a las muestras de esputo (desde 92,3% a los 7 días, hasta 60,8% a más de 15 días). Un estudio observó que la aplicación de una regla basada en realizar una prueba de detección de anticuerpos a todos los casos negativos según RT-PCR, incrementó la sensibilidad diagnóstica desde un 51,9% hasta un 98,6%, reduciendo el porcentaje de falsos negativos. CONCLUSIONES: Se observó mayor positividad de las pruebas de RT-PCR durante los primeros días del inicio de síntomas, comparado con las pruebas de detección de anticuerpos. Conforme transcurre la enfermedad, la tendencia se revierte, mostrando las pruebas de detección de anticuerpos IgG/IgM una mayor sensibilidad en comparación con las pruebas de RT-PCR. La reducción de la positividad en las pruebas de RT-PCR conforme transcurre la enfermedad, es más acentuada en muestras de hisopado faríngeo, en comparación con muestras de esputo. La aplicación de una regla basada en realizar una prueba de detección de anticuerpos a todos los casos negativos según RT-PCR, incrementa la sensibilidad desde un 51,9% hasta un 98,6%, reduciendo el porcentaje de falsos negativos. Los hallazgos de la presente revisión apoyan el uso complementario de pruebas de RT-PCR y de detección de anticuerpos para el diagnóstico de pacientes con COVID-19.(AU)

Precisión diagnóstica de pruebas de detección de antígenos para SARS-CoV-2 / Precisão diagnóstica dos testes de triagem de antígenos para SARS-CoV-2

ANTECEDENTES: Los coronavirus son una familia de virus causantes de enfermedades respiratorias, digestivas y del sistema nervioso en humanos y animales. En diciembre de 2019, se identificó en la provincia de Wuhan, China una cepa de coronavirus nunca antes encontrada en humanos, la cual recibió el nombre de SARSCoV-2. La infección por SARS-CoV-2 se ha extendido a más de 209 países y fue declarada como pandemia por la Organización Mundial de la Salud. En nuestro país, se ha reportado 28 699 casos y un total de 782 fallecidos. La técnica molecular estándar para detectar SARS-CoV-2 es la reacción en cadena de la polimerasa con transcriptasa inversa (RT-PCR). Sin embargo, se requieren pruebas rápidas que disminuyan el tiempo de espera entre la toma de muestras y la entrega de resultados, con la finalidad de descartar casos sospechosos, mejorar el pronóstico clínico y contener el contagio de la infección. Las pruebas basadas en la detección de antígenos permiten detectar microorganismos o fragmentos de los mismos en muestras clínicas, y pueden contribuir a mejorar la oportunidad del diagnóstico, en comparación con las pruebas de RT-PCR. OBJETIVO: Describir la evidencia científica disponible sobre la precisión diagnóstica de las pruebas rápidas de detección de antígenos para SARS-CoV-2. MÉTODO: Búsqueda sistemática en Medline (Pubmed), Cochrane Central Register of Controlled Trials (CENTRAL), Medrxiv y Chinese Clinical Trial Registry (CCTR) de estudios en idioma español o inglés publicados entre el 01 de diciembre de 2019 y el 22 de abril de 2020, complementada con una búsqueda en Google Scholar. La calidad metodológica se evaluó usando el instrumento QUADAS 2. RESULTADOS: Los resultados de un estudio desarrollado en muestras clínicas de 239 pacientes sospechosos de COVID19 procedentes de siete hospitales en China mostraron una sensibilidad de 68%, y especificidad de 100% de una prueba de detección de la proteína de la nucleocápside (antígeno N) del SARS-CoV-2, en comparación con RT-PCR como estándar de referencia. La evaluación de calidad mostró una probabilidad alta de sesgo en las dimensiones de selección de individuos y prueba de referencia. En cuanto a la aplicabilidad de los resultados del estudio, existe una probabilidad incierta en la dimensión de selección de los pacientes. CONCLUSIONES: Comparado con la prueba de reacción en cadena de la polimerasa con transcriptasa inversa (RTPCR), la prueba de detección de antígenos mostró una sensibilidad de 68% y especificidad de 100% para el diagnóstico para SARS-CoV-2. Con una prevalencia de 87% (prevalencia de COVID-19 del estudio) y según la precisión diagnóstica reportada, la probabilidad de tener COVID-19 frente a un resultado negativo con la prueba de detección de antígenos es del 68%. Esta probabilidad se ve afectada por la prevalencia de la enfermedad, siendo menor cuando la prevalencia disminuye. La calidad de la evidencia para la precisión diagnóstica de las pruebas de detección de antígenos contra SARS-CoV-2 es muy baja, pues procede de un único estudio con alto riesgo de sesgo, imprecisión en sus resultados y aplicabilidad incierta.(AU)

Peer distribution of HIV self-test kits to men who have sex with men to identify undiagnosed HIV infection in Uganda: A pilot study.

INTRODUCTION: One-in-three men who have sex with men (MSM) in Uganda have never tested for HIV. Peer-driven HIV testing strategies could increase testing coverage among non-testers. We evaluated the yield of peer distributed HIV self-test kits compared with standard-of-care testing approaches in identifying undiagnosed HIV infection. METHODS: From June to August 2018, we conducted a pilot study of secondary distribution of HIV self-testing (HIVST) through MSM peer networks at The AIDS Support Organization (TASO) centres in Entebbe and Masaka. Peers were trained in HIVST use and basic HIV counselling. Each peer distributed 10 HIVST kits in one wave to MSM who had not tested in the previous six months. Participants who tested positive were linked by peers to HIV care. The primary outcome was the proportion of undiagnosed HIV infections. Data were analysed descriptively. RESULTS: A total of 297 participants were included in the analysis, of whom 150 received HIVST (intervention). The median age of HIVST recipients was 25 years (interquartile range [IQR], 22-28) compared to 28 years IQR (25-35) for 147 MSM tested using standard-of-care (SOC) strategies. One hundred forty-three MSM (95%) completed HIVST, of which 32% had never tested for HIV. A total of 12 participants were newly diagnosed with HIV infection: 8 in the peer HIVST group and 4 in the SOC group [5.6% vs 2.7%, respectively; P = 0.02]. All participants newly diagnosed with HIV infection received confirmatory HIV testing and were initiated on antiretroviral therapy. CONCLUSION: Peer distribution of HIVST through MSM networks is feasible and effective and could diagnose more new HIV infections than SOC approaches. Public health programs should consider scaling up peer-delivered HIVST for MSM.

Development of immunochromatographic device as a point-of-care tool for serodiagnosis of human strongyloidiasis cases.

Human strongyloidiasis is an important gastrointestinal disease with an estimated 30 to 100 million people infected. Prevalence is generally underestimated since many infections are asymptomatic, and traditional diagnostic tests based on parasitological examination of stool samples are not adequately sensitive. Serological tests are useful and supportive but are still only available in a reference research setting. We made an immunochromatographic test (ICT) kit for rapid serodiagnosis of human strongyloidiasis. The antigen used in the ICT kit was extracted from larvae of Strongyloides stercoralis. Diagnostic efficacy of the kit was evaluated using human serum samples from strongyloidiasis patients, healthy persons, and those with other parasitoses. When using a cutoff level of 0.5 or above, the diagnostic sensitivity, specificity, and positive and negative predictive values at the prevalence of infection of 34.4%, were 93.3%, 83.7%, 76.7%, and 95.6%, respectively. This ICT kit is easy to use at the point-of-care and a result can be obtained in 15 min. Sophisticated instruments and highly trained staff are not required. It can be used in several diagnostic and public-health settings, e.g., prevalence surveys in endemic areas, confirmation and monitoring of cure post-treatment, diagnosis and screening of infected but asymptomatic individuals, and populations "at risk" for hyperinfection syndrome or disseminated strongyloidiasis if they are given immunosuppressive treatment for other conditions.

Performance of a rapid diagnostic test for screening of hepatitis C in a real-life prison setting.

BACKGROUND: Hepatitis C virus (HCV) point-of-care testing using rapid diagnostic test (RDT) is the solution for large-scale, feasible, fast and reliable screening of HCV infection. OBJECTIVES: The aim of this study was to evaluate the diagnostic performance of HCV RDT for screening of HCV infection in a real-life prison setting. STUDY DESIGN: This study was conducted on individuals admitted and incarcerated in the Central Prison of Karaj, 2017-2018. For all inmates, anti-HCV testing using a RDT on finger-stick blood in the prison and ELISA at the laboratory were performed. For evaluation of reproducibility, more than 1000 cases were recruited for re-evaluation of the HCV RDT using anticoagulated blood in the laboratory. RESULTS: Among 1788 participants, 76 (4.25%) and 106 (5.93%) were positive for anti-HCV using RDT and ELISA, respectively. Among 34 cases with discordant results using the RDT and ELISA, 17 were the result of testing error in prison, 7 false positive of ELISA and 10 false negative of RDT in individuals with HCV spontaneous clearance. The sensitivity of the RDT with inclusion of testing error in prison for detection of anti-HCV was 75%. However, with exclusion of testing error in prison and considering HCV RNA as the reference method for diagnosis of current HCV infection the sensitivity reached 100%. The RDT was 100% reproducible using both evaluations in prison and the laboratory. CONCLUSIONS: The RDT is a reliable and feasible method for screening of anti-HCV in settings such as a prison. However, the testing should be performed in a standard procedure to have the optimal diagnostic performance.

Evaluation of dot-blot test for serological diagnosis of bovine brucellosis

Abstract The objective of this study was to standardize and validate the dot-blot test for the serological diagnosis of bovine brucellosis, compare the results with those found in the 2-mercaptoethanol (2-ME) and complement fixation test (CF), and estimate the relative sensitivity and specificity of the dot-blot compared to these tests. Fifty bovine blood serum samples were used for the test standardization, and 1315 samples were used for evaluation and comparison between the tests; the results were compared using the Kappa indicator. At the end of standardization, it was established as optimal for the antigen obtained from Brucella abortus B19 after passing through a microorganism rupture process, the blood serum samples diluted at 1:100, and the conjugate at 1:30,000. The comparison of the dot-blot results with 2-ME showed Kappa index of 0.9939, sensitivity of 99.48%, and specificity 99.91%, with CF, Kappa index of 0.8226, sensitivity 100% and specificity 95.32%. Using the combination of the test results 2-ME and CF to establish the true condition of the animal, the dot-blot showed relative sensitivity of 100%, and relative specificity of 99.91%. The evaluated test proved to be effective and reliable, besides being easy to handle and interpret the results.

Development of a sensitive immunochromatographic kit using fluorescent silica nanoparticles for rapid serodiagnosis of amebiasis.

We have previously shown that the C-terminal region of the intermediate subunit of Entamoeba histolytica galactose- and N-acetyl-D-galactosamine-inhibitable lectin (C-Igl) is a useful antigen for serodiagnosis of amebiasis. An immunochromatographic kit was developed using fluorescent silica nanoparticles coated with C-Igl prepared in Escherichia coli. Samples for examination were added to the freeze-dried particles and then applied to the immunochromatographic device, in which a test line on the membrane was also coated with C-Igl. Fluorescent intensity was measured using a hand-held reader. In an evaluation of the kit using a human monoclonal antibody, the minimum amount of C-Igl specific antibody showing positive results was 100 pg. In the evaluation of serum samples with different antibody titers in indirect immunofluorescent antibody tests in the kit, 20 µL of serum was sufficient to obtain positive results at 30 min. Serum samples from symptomatic patients with amebic colitis and amebic liver abscess and those from asymptomatic E. histolytica-cyst carriers showed positive results in the kit. Based on evaluation using sera from healthy controls and patients with other infectious diseases, the sensitivity and specificity of the kit were 100 and 97.6%, respectively. Therefore, we conclude that the newly developed kit is useful for rapid serodiagnosis of amebiasis.

The performance of the Alere HIV combo point-of-care test on stored serum samples; useful for detection of early HIV-1 infections?

INTRODUCTION: The Alere HIV-1/2 Antigen/Antibody Combo point-of-care test is a commercially available 4th-generation rapid test for the diagnosis of HIV infection, including acute infection. We evaluated the sensitivity of this test in samples from patients with acute, recent or chronic HIV-1 infection. METHODS: A validation of the test was performed using 89 HIV-positive serum samples collected in 2008-2016, that were stored at -20°C. Twenty-three samples were only p24-positive (acute infection); 49 samples were antibody-positive and p24-positive (recent infection); 17 samples were only antibody-positive (chronic infection). HIV infection was confirmed by standard-of-care assays and PCR. Samples came from patients attending an outpatient clinic for STDs at the Public Health Department and from patients within the Erasmus Medical Center, Rotterdam, the Netherlands. RESULTS: The overall sensitivity of the test for diagnosing HIV infection based on detection of p24 antigen and/or antibodies was 92% (95% CI 86% to 98%) (82/89). In acute sera with only p24 antigen positivity, the sensitivity of the test decreased to 65% (95% CI 46% to 85%) (15/23). When both antibody and antigen testing were positive, the p24 sensitivity was only 24% (95% CI 12% to 36%) (12/49), but in these sera the final test result was positive in all sera (49/49) due to the positive antibody component. CONCLUSIONS: In a laboratory setting, this test has an overall sensitivity of 92% to detect any stage of HIV-1 infection using sera specimens. It performs relatively well in detecting early HIV and may be beneficial as an initial screening in patients with a recent exposure to HIV. Additional testing in a laboratory setting remains mandatory as a proportion of acute HIV-1 infections are missed with this test.

Comparison of two automated instruments for Epstein-Barr virus serology in a large adult hospital and implementation of an Epstein-Barr virus nuclear antigen-based testing algorithm.

Serology remains the mainstay for diagnosis of Epstein-Barr virus (EBV) infection. This study compared two automated platforms (BioPlex 2200 and Architect i2000SR) to test three EBV serological markers: viral capsid antigen (VCA) immunoglobulins of class M (IgM), VCA immunoglobulins of class G (IgG) and EBV nuclear antigen-1 (EBNA-1) IgG. Using sera from 65 patients at various stages of EBV disease, BioPlex demonstrated near-perfect agreement for all EBV markers compared to a consensus reference. The agreement for Architect was near-perfect for VCA IgG and EBNA-1 IgG, and substantial for VCA IgM despite five equivocal results. Since the majority of testing in our hospital was from adults with EBNA-1 IgG positive results, post-implementation analysis of an EBNA-based algorithm showed advantages over parallel testing of the three serologic markers. This small verification demonstrated that both automated systems for EBV serology had good performance for all EBV markers, and an EBNA-based testing algorithm is ideal for an adult hospital.

Subtractive phage display selection for screening and identification of peptide sequences with potential use in serodiagnosis of paracoccidioidomycosis caused by Paracoccidioides brasiliensis.

Paracoccidioidomycosis (PCM) is a systemic granulomatous disease endemic in Latin America whose aetiologic agents are the thermodimorphic fungi Paracoccidioides brasiliensis and Paracoccidioides lutzii. Despite technological advances, some problems have been reported for the fungal antigens used for serological diagnosis, and inconsistencies among laboratories have been reported. The use of synthetic peptides in the serological diagnosis of infectious diseases has proved to be a valuable strategy because in some cases, the reactions are more specific and sensitive. In this study, we used a subtractive selection with a phage display library against purified polyclonal antibodies for negative and positive PCM sera caused by P. brasiliensis. The binding phages were sequenced and tested in a binding assay to evaluate its interaction with sera from normal individuals and PCM patients. Synthetic peptides derived from these phage clones were tested in a serological assay, and we observed a significant recognition of LP15 by sera from PCM patients infected with P. brasiliensis. Our results demonstrated that subtractive phage display selection may be useful for identifying new epitopes that can be applied to the serodiagnosis of PCM caused by P. brasiliensis. SIGNIFICANCE AND IMPACT OF THE STUDY: Currently, there is no standardized method for the preparation of paracoccidioidomycosis (PCM) antigens, which has resulted in differences in the antigens used for serological diagnosis. Here, we report a procedure that uses subtractive phage display selection to select and identify new epitopes for the serodiagnosis of PCM caused by Paracoccidioides brasiliensis. A synthetic peptide obtained using this methodology was successfully recognized by sera from PCM patients, thus demonstrating its potential use for improving the serodiagnosis of this mycosis. The development of synthetic peptides for the serodiagnosis of PCM could be a promising alternative for the better standardization of diagnoses among laboratories.

Análise comparativa da reatividade anti-LID-1, NDO-LID, NDO-HSA e PGL-1 em hanseníase / Comparative analysis of the reactivity anti-LID-1, NDO-LID, NDO-HSA and PGL-1 in leprosy

A infecção subclínica pode ser avaliada por meio de teste sorológico, que determina imunoglobulinas circulantes. O objetivo do presente estudo foi analisar a reatividade de diferentes antígenos em casos novos de hanseníase, contatos domiciliares de casos e em população de área endêmica, com o intuito de identificar o melhor antígeno para o diagnóstico sorológico da hanseníase e detecção de indivíduos infectados pelo Mycobacterium leprae.Trata-se de um estudo transversal de natureza exploratória e analítica. A reatividade anti-LID-1, NDO-LID, NDO-HSA e PGL-1 foi avaliada por meio do enzyme-linked immunosorbentassay. Foram analisadas amostras de sangue total em papel de filtro Whatman de 2494indivíduos da população de sete municípios da microrregião de Almenara e de soro de 94casos novos de hanseníase e 104 contatos domiciliares de casos residentes no município de Uberlândia. O Banco de Dados foi criado no Software Epi Info versão 3.5.1 e análise realizada no software Statistical Package for the Social Sciences for Windows 18 e no GraphPad Prism versão 5. Para análise estatística foram utilizados os seguintes testes: Kolmogorov-Smirnov, Kruskal-Wallis one-way (H), Mann-Whitney (U) com correção de Bonferroni, kappa, Spearman (rho), teste Qui-quadrado de Pearson e regressão logística binária. Foi observado maior soropositividade no grupo de casos multibacilares (MB), em contatos domiciliares de casos MB e nos indivíduos residentes nos municípios de Almenara e Jequitinhonha. Obteve-se correlação positiva entre a sorologia e o índice baciloscópico,concordância substancial e significativa no grupo de casos novos de hanseníase e correlação positiva para todos os antígenos testados. Os testes anti-LID-1 e anti-NDO-LID apresentaram melhor performance para identificar os contatos domiciliares e ou indivíduos da população...

The subclinical infection can be evaluated by serologic test which determine circulating immunoglobulins. The aim of this study was to analyze the reactivity of different antigens inleprosy cases, household contacts of index cases and the population of the endemic area toidentify the best antigen for the diagnosis of leprosy and detection of individuals infected with Mycobacterium leprae. It is a cross-sectional study of exploratory and analytical nature. There activity anti-LID-1, NDO-LID, NDO-HAS e PGL-1 were evaluated using the enzyme linke dimmunosorbent assay. The whole blood in What man filter paper of 2494 individuals from the general population of seven municipalities in the micro-Almenara and serum of 94 patients with leprosy and 104 household contacts of patients residing in Uberlândia were analyzed. The database was created in Epi Info software version 3.5.1 and analysis in the software Statistical Package for Social Sciences for Windows 18 and GraphPad Prism version5. For statistical analysis the following tests were used: Kolmogorov-Smirnov, Kruskal Wallisone-way (H), Mann-Whitney (U) with Bonferroni correction, kappa, Spearman (rho), chisquaretest of Pearson and binary logistic regression. Identied higher seropositivity in the group of MB patients, household contacts of MB patients and in individuals living in the municipalities of Almenara and Jequitinhonha. Observed positive correlation between serology test and bacterial index, substantial agreement and significant in patients positive and positive correlation for all antigens. The LID-1 and NDO-LID antigens showed greater ability to identify household contacts or the general population infected with M. leprae, but the performance of the NDO-LID was better. The native PGL-1 had higher seropositivity than the NDO-HSA for all clinical forms of leprosy and household contacts. The seropositivity prevalence in the general population was higher than the detection rate of leprosy...

Serodiagnosis of human hydatidosis with an ELISA developed based on antigens derived from sheep hydatid cysts and comparison with a commercial human ELISA kit.

OBJECTIVE: To explore the serodiagnosis of hydatid cyst in human using different antigens of sheep (hydatid fluid, Somatic and Excretory/secretory antigens of protoscolex) by ELISA and compares this result with commercial human ELISA kit. METHODS: One hundred blood samples from patients with history of severe abdominal pain and eosinophilia were obtained. Ten serum samples were obtained from surgically and pathologically confirmed cystic echinococcosis patients from Mashhad university hospital as positive control and 5 serum samples from infant under one year old as negative control. Blood samples were centrifuged at 3 000µg at 20 °C for 15 min and sera were stored at -20 °C. First, these samples were tested for the presence of antibody by commercial human ELISA. Then, ELISA was developed on microplates coated with hydatid fluid, Somatic and Excretory/secretory antigens of protoscolex of sheep. RESULTS: The results of this study as analyzed by Kappa test showed that, hydatid fluid antigen could be used as a precise source of detection in indirect ELISA test. CONCLUSIONS: Hydatid fluid in comparison with Excretory-secretory and somatic antigens showed more compatibility agreement in kappa test which can be used for further studies in development of any ELISA test for diagnosis of human hydatidosis.

Medical devices; ovarian adnexal mass assessment score test system; labeling; black box restrictions. Final rule.

The Food and Drug Administration (FDA) is amending the regulation classifying ovarian adnexal mass assessment score test systems to restrict these devices so that a prescribed warning statement that addresses a risk identified in the special controls guidance document must be in a black box and must appear in all labeling, advertising, and promotional material. The black box warning mitigates the risk to health associated with off-label use as a screening test, stand-alone diagnostic test, or as a test to determine whether or not to proceed with surgery.

Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads.

This study developed and validated a high-throughput human papillomavirus (HPV) serology method based on Luminex technology, using pseudovirions (PsVs) of eight mucosal HPV types (HPV-6, -11, -16, -18, -31, -45, -52 and -58) and two cutaneous HPV types (HPV-5 and -38) bound to heparin-coated beads. Analysis with neutralizing type-specific monoclonal antibodies against the included HPV types indicated the type specificity of the assay. Analysis of negative-control serum samples from 63 children and 71 middle-aged women with up to one lifetime sexual partner indicated high specificity. Positive-control serum samples from subjects with known HPV DNA status or clinical diagnosis found expected sensitivities for most of the HPV types in 219 European serum samples, but lower than expected in 124 samples from Africa. HPV-45 and -52 did not react as expected with the human serum samples. The PsV-Luminex method was used to determine the HPV-seropositivity-associated relative risk for future cervical cancer using 208 serum samples from a prospective study of 18 814 women followed for 23 years, analysed previously with standard HPV-16 ELISA. The PsV-Luminex method gave similar results to ELISA (kappa=0.77). As expected, HPV seropositivities assayed using the PsV-Luminex method found an increased risk of cervical cancer for HPV-16 [odds ratio (OR)=7.7, 95 % confidence interval (CI)=2.6-23] and HPV-31 (OR=4.1, 95 % CI=1.6-10.8), non-significant tendencies for increased risk for other mucosal HPV types and no risk for the cutaneous HPV types. In summary, multiplexed HPV serology using mammalian-derived PsVs selected for native conformation by binding to heparin-coated beads was validated as a high-throughput HPV serological method for most of the analysed HPV types.